• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations.

作者信息

Parkins Michael D, Thornton Christina S

机构信息

Department of Medicine.

Department of Microbiology, Immunology & Infectious Diseases, and.

出版信息

Ann Am Thorac Soc. 2024 May;21(5):696-698. doi: 10.1513/AnnalsATS.202401-118ED.

DOI:10.1513/AnnalsATS.202401-118ED
PMID:38691006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11109905/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/150d/11109905/b9ba9834d62a/AnnalsATS.202401-118EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/150d/11109905/5754e80f4c59/AnnalsATS.202401-118EDfx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/150d/11109905/b9ba9834d62a/AnnalsATS.202401-118EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/150d/11109905/5754e80f4c59/AnnalsATS.202401-118EDfx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/150d/11109905/b9ba9834d62a/AnnalsATS.202401-118EDf1.jpg

相似文献

1
STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations.停止在囊性纤维化肺部加重期使用皮质类固醇。
Ann Am Thorac Soc. 2024 May;21(5):696-698. doi: 10.1513/AnnalsATS.202401-118ED.
2
Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.C反应蛋白作为预测囊性纤维化患者肺部加重严重程度生物标志物的作用。
BMC Pulm Med. 2014 Sep 23;14:150. doi: 10.1186/1471-2466-14-150.
3
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].[中国专家共识声明：囊性纤维化的诊断与治疗（2023年）]
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971.
4
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.囊性纤维化肺部指南：肺部急性加重的治疗
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.
5
Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.口服皮质类固醇治疗囊性纤维化肺部加重：从过去探寻未来
Eur Respir J. 2024 Oct 3;64(4). doi: 10.1183/13993003.01049-2024. Print 2024 Oct.
6
Reply to: Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.回复：用于囊性纤维化肺部加重期的口服皮质类固醇：在过往中探寻未来
Eur Respir J. 2024 Oct 3;64(4). doi: 10.1183/13993003.01577-2024. Print 2024 Oct.
7
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.辅助全身皮质类固醇治疗囊性纤维化肺部加重。
Ann Am Thorac Soc. 2024 May;21(5):716-726. doi: 10.1513/AnnalsATS.202308-673OC.
8
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.全身性皮质类固醇在儿童囊性纤维化肺部加重期治疗中的应用
Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC.
9
[Management of patients with cystic fibrosis: role of corticosteroid therapy].[囊性纤维化患者的管理：皮质类固醇疗法的作用]
Rev Mal Respir. 2003 Apr;20(2 Pt 2):S137-9.
10
Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosis.囊性纤维化肺部感染加重的抗菌药物优化治疗：II. 变应性支气管肺曲霉病的治疗。
Pediatr Pulmonol. 2020 Dec;55(12):3541-3572. doi: 10.1002/ppul.25080. Epub 2020 Sep 29.

引用本文的文献

1
How Effectively Can Oxidative Stress and Inflammation Be Reversed When CFTR Function Is Pharmacologically Improved?当CFTR功能通过药物得到改善时，氧化应激和炎症能在多大程度上得到有效逆转？
Antioxidants (Basel). 2025 Mar 4;14(3):310. doi: 10.3390/antiox14030310.

本文引用的文献

1
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.辅助全身皮质类固醇治疗囊性纤维化肺部加重。
Ann Am Thorac Soc. 2024 May;21(5):716-726. doi: 10.1513/AnnalsATS.202308-673OC.
2
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.囊性纤维化肺部加重的STOP2研究中呼吸道病毒感染的患病率及临床影响
Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC.
3
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location.
与囊性纤维化相关的肺部恶化治疗地点相关的特征。
J Cyst Fibros. 2024 Mar;23(2):278-281. doi: 10.1016/j.jcf.2023.10.004. Epub 2023 Oct 5.
4
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.全身性皮质类固醇在儿童囊性纤维化肺部加重期治疗中的应用
Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC.
5
Antipseudomonal treatment decisions during CF exacerbation management.在 CF 加重期管理中对抗假单胞菌的治疗决策。
J Cyst Fibros. 2022 Sep;21(5):753-758. doi: 10.1016/j.jcf.2022.04.006. Epub 2022 Apr 22.
6
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.一项针对伴有肺部恶化的囊性纤维化患者的抗菌疗程随机试验中的医疗保健成本。
J Cyst Fibros. 2022 Jul;21(4):594-599. doi: 10.1016/j.jcf.2022.03.001. Epub 2022 Mar 14.
7
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.C-反应蛋白（CRP）作为肺部恶化表现和治疗反应的生物标志物。
J Cyst Fibros. 2022 Jul;21(4):588-593. doi: 10.1016/j.jcf.2021.12.003. Epub 2021 Dec 18.
8
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.静脉用抗菌药物治疗肺部感染恶化后，治疗部位与临床结局的相关性。
J Cyst Fibros. 2022 Jul;21(4):574-580. doi: 10.1016/j.jcf.2021.11.009. Epub 2021 Nov 29.
9
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.一项囊性纤维化肺部感染加重治疗中抗菌疗程的随机临床试验。
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1295-1305. doi: 10.1164/rccm.202102-0461OC.
10
Inhaled corticosteroids for cystic fibrosis.用于囊性纤维化的吸入性皮质类固醇。
Cochrane Database Syst Rev. 2019 Jul 4;7(7):CD001915. doi: 10.1002/14651858.CD001915.pub6.